Hypertension is a common medical problem that almost all physicians must deal with, but what’s the rational blood pressure target?
What’s the Target of the New ACC/AHA Performance Measures?
January 08, 2020
We asked the Deputy Editors of DynaMed for their top clinical studies or stories of 2019.
Top Clinical Stories of 2019 from the DynaMed Deputy Editors
January 06, 2020
See how Richard Crookes, an EBSCO Information Services Senior Customer Engagement Manager, helps medical institutions across the UK make the most of their medical library resources.
Q&A with Richard Crookes: The Life and Times of an EBSCO Senior Customer Engagement Manager
November 05, 2019
A possible increased risk of skin cancer with thiazide diuretics is unlikely to change prescribing. Read more in the latest EBM Focus.
EBM Focus: Thiazide Diuretics and Skin Cancer? Don’t Get Burned by the Hype
July 10, 2019
Clinical educator Dan Ostrovsky, Associate Professor of Internal Medicine and Pediatrics at Duke University, offers teaching tips to maximize new resident understanding and lifelong learning.
Teaching Tips for Clinical Educators at the Start of the New Internship/Resident Year
June 27, 2019
A new trial adds to the evidence that MMR vaccination does not increase risk of autism, even among high-risk children.
EBM Focus: Continuing to Debunk Ties Between MMR Vaccination and Autism Spectrum Disorder
June 25, 2019
A new trial adds to the evidence for a benefit of thrombolytics for stroke beyond four and a half hours.
EBM Focus: Pushing the needle — Benefit of Thrombolytics for Stroke beyond Four and a Half Hours
June 18, 2019
A new study evaluates the evidence behind clinical practice recommendations in cardiology guidelines. Read the EBM Focus article — concise summaries of clinical trials most likely to inform clinical practice — curated by the DynaMed® editorial team.
EBM Focus: Expert Opinion and Low-quality Evidence Still Drive Strong Recommendations in Cardiology
June 10, 2019
Dr. Martin (Marty) Mayer discusses the long-running problem of misunderstanding and misapplying the concept of “statistical significance” and the p value.
What’s so Significant About (Statistical) Significance?
May 30, 2019
A new trial shows renal protection by canagliflozin in patients with type 2 diabetes. Read the EBM Focus article — concise summaries of clinical trials most likely to inform clinical practice — curated by the DynaMed® editorial team.
EBM Focus: Canagliflozin for Renal Protection—Not the Next ACE Inhibitor
May 29, 2019
© 2020 EBSCO Industries, Inc. All rights reserved